[{"orgOrder":0,"company":"Batavia Bioscience","sponsor":"IAVI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"VSV\u2206G-SARS-CoV-2","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Batavia Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Batavia Bioscience \/ IAVI","highestDevelopmentStatusID":"4","companyTruncated":"Batavia Bioscience \/ IAVI"},{"orgOrder":0,"company":"Batavia Bioscience","sponsor":"Valneva","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Inactivated polio vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Batavia Bioscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Batavia Bioscience \/ Batavia Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Batavia Bioscience \/ Batavia Biosciences"},{"orgOrder":0,"company":"Batavia Bioscience","sponsor":"Candel Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Large molecule","year":"2024","type":"Partnership","leadProduct":"CAN-3110","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Batavia Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Batavia Bioscience \/ Candel Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Batavia Bioscience \/ Candel Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Batavia Bioscience

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The partnership aims to accelerate the development and production of CAN-3110, an oncolytic viral immunotherapy for glioma brain tumors, based on a replication attenuated Herpes Simplex Virus (HSV).

                          Brand Name : CAN-3110

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          March 21, 2024

                          Lead Product(s) : CAN-3110,Cyclophosphamide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Candel Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Under the terms of the agreement, Valneva will manufacture the sIPV vaccine for clinical trial purposes in its state-of-the-art GMP polio manufacturing facility operated under GAPIII[2] polio containment in Solna, Sweden, using Batavia’s process.

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          June 16, 2020

                          Lead Product(s) : Inactivated polio vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Recipient : Valneva

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : By working with Batavia Biosciences, IAVI intends to develop an end-to-end platform for flexible, low-cost production of epidemic preparedness vaccines, including vaccines against a group of viruses that cause hemorrhagic fevers and other emerging viral...

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          March 05, 2020

                          Lead Product(s) : VSV∆G-SARS-CoV-2

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : IAVI

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank